Nkarta
NKTX | NASDAQ
$1.21
+$0.02 (+1.68%)
At close: Nov 16, 2026, 4:00 PM ET
$1.21
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Nkarta Company Profile
Company profile explainedCompany Profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Paul J. Hastings | Chief Executive Officer & Director |
| Nadir Mahmood | President and Principal Accounting & Financial Officer |
| Shawn Rose | Chief Medical Officer and Head of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 4 | Filing |
| Jun 11, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
Nkarta
| Country | United States |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Paul J. Hastings |
Contact Details
1150 Veterans Boulevard South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | NKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001787400 |
| CUSIP Number | 65487U108 |
| ISIN Number | US65487U1088 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove NKTX